Auto-Injector Market Research Report- Forecast till 2027

Auto-Injector Market Research Report: By Product Type (Disposable, Reusable), Application (Anaphylaxis, Multiple Sclerosis, Diabetes, Allergies, Rheumatoid Arthritis, Others), Distribution Channel (Online Retailer, Pharmacy, Others), End-User (Home Care Settings, Hospitals & Clinics, Ambulatory Surgical Centers), and Region (Americas, Europe, Asia-Pacific, and Middle East and Africa)- Forecast till 2027

ID: MRFR/MED/1514-HCR | February 2021 | Region: Global | 85 pages

Auto-Injector Market Overview 


The auto-injector market size is projected to grow by 22% in the forecast period. The auto-injector is a type of syringe that has pre-dosage drugs. It triggers the right amount of drugs in the syringe. Injecting a measured amount of drugs into a sliding motion is an exceptional feature of this device. Auto-injectors are useful for personal purposes. It is an exceptional injector for self-administration. Also, it is beneficial for epinephrine and migraine conditions. For medical and urgent treatments the usage of an auto-injector is essential. There are plenty of benefits of auto-injectors.


 Few advantages of the auto-injectors are it is a suitable syringe for individuals with phobia disorders. It lessens the accidents of the needle getting stuck into the body. Also, it is useful for proper dosage quantity and injection effectiveness. The auto-injectors are receiving plenty of awareness in recent years. Today, due to lockdown many are rapidly adopting auto-injectors.


Many patients and their families learn self-administration. It saves effort and time of visiting hospitals for very injections. With the auto-injectors, arthritis patients, multiple sclerosis and other chronic disease patients can benefits. Patients with chronic illness require everyday injections. With the help of auto-injectors, the accuracy and effectiveness of the medicine are high. In the forecast year, the auto-injector market value will reach 125.32 million. 


Covid analysis 


The outbreak of covid 19 has lead to a global health crisis. The health sector is more during this period. Demand for non-essential medical services has reduced massively. The number of patients visiting hospitals for treatment other than covid 19 reduced to 40%. Patients are delaying the treatment and injections required for chronic illness. It has a declining impact on the auto-injector market.


There is a slowdown in the launch of treatments required for chronic illness. Due to these factors, the auto injector’s market growth is slowing down. However, the pharmaceutical company market is key end-users for auto-injectors. It is accelerating the demand for auto inject in the current year. The development of pharmaceutical companies is creating a positive impact on the auto-injector market. Overall the auto-injector market analysis trend remains positive during this period. 


Market dynamics 



  • Crucial market drivers 


The rise of anaphylaxis is severe in many regions. It is a dangerous food reaction that causes deadly allergies. One out of 1000 people in the population has an anaphylaxis reaction. Further, the patients suffering from this disorder is high during anesthesia. Epinephrine is the primary treatment available for anaphylaxis. The pharmaceutical companies are raising their production of auto-injectors that contain epinephrine. 


The pharma companies are raising the launch of advanced auto-injectors. The need for injector caps, injection dosage and audible click detection is improving in the new models. The availability of these injectors is growing during the forecast period. Earlier, the auto injector’s cases were fewer. However, in many patients, it is effortlessly available for home use. Increased adoption and use of auto-injectors will grow the auto-injector market size. The growth of the geriatric population is another demand driving factor of auto-injector market. auto-injector market profitability will increase due to these factors. 



  • Market growth opportunities 


Due to the covid 19 pandemic, new protocols are created for a patient visiting the hospitals. During non-emergency cases, the healthcare industry is taking preventive measures. These protocols help to stop the spread of the covid virus. The need to limit the number of patients visiting the hospital for non-emergency purposes is rising growth opportunities. The presence of home injection is highly prevalent among many patients.


Especially, the patient with chronic illnesses finds these auto-injectors highly beneficial. Also, the increasing awareness about this injector is another factor leading to growth opportunities. Rheumatoid arthritis is another crucial reason for the growth of the auto-injector market. Patients with a severe allergy do not need to delay the treatment. With the help of auto-injectors, quick treatment is possible. In the covid 19, the application of auto-injectors has expanded. In the upcoming years, more patients and end-users will have a high demand for auto-injectors. The auto-injector market expansion rate for the market is immense in the forecast year. All these will lead exceptional auto-injector market growth opportunities. 



  • The market restraints 


The traditional injections are invasive and painful. It is leading to more demand for clinical drugs, oral, nasal and other modes of treatment. The oral route of medicines is preferred by half the population. The ease of use, convenience and cost are some of the benefits of clinical drugs. It is a safe and acceptable form of medication for many. Today, digital pharmacy services are expanding rapidly. It is a reliable form of delivering drugs to patients.


The growth of drug delivery market restraints the growth of the auto-injector market. The anxiety about needles is less due to these drugs. There is a decline in injection treatment in many regions. It is changing the customer preference towards the painless drug market. From children to chronic illness patients prefer fewer pain meds of treatment. The anxiety of needles is the key factor restraining auto-injector market growth. 



  • The market challenges 


There are different types of chronic illnesses requiring daily injections. However, the versatility of the illness creates different requirements for auto-injectors. The injection capacity, dosage, length and thickness require being different for each of the medications. These factors lead to different types of auto-injectors.


 It is a challenging aspect of the market. The non-availability of proper auto-injectors and lack of product versatility can have a declining effect on the auto-injector market. The OEM lacks the knowledge of manufacturing multiple drugs. The key players are taking efforts to eradicate these market challenges. With more research, the market is trying to cope with this challenge. 



  • Cumulative growth analysis 


The overall growth rate of the auto-injector market is stable in the forecast period. There are few factors that continually propel the demand of the market. The rising urgency of injection in allergic cases is stirring the demand for the auto-injector market. Due to chronic illness, the adoption of auto-injectors is tremendous in many regions. The awareness about self-administration is leaving to more profits for the market.


Further, the key players are increasing the availability of these auto-injectors. Due to convenience and ease of access many users prefer auto-injectors. The anxiety about the injection and growth of digital pharmacy services is a retaining factor of auto-injector market. Overall the growth trend of the auto-injector market is promising for the forecast period. 



  • The value chain analysis 


The Asia Pacific market is expected to outgrow other regional players in the forecast period. The demand for auto-injectors is high in this region. The immense growth of diabetes patients is raising the demand for the product. Further, the health care infrastructure is developing at an exponential pace.


It leads to more manufacture of auto-injectors. Home care and self-administration in chronic illnesses is surging in this region. For non-urgent cases, many patients and their families learn to use auto injectors. The presence of top auto-injector market companies is advantageous for market growth. There is constant development and high demand for auto-injectors in Asia pacific region. 


Segment overview 


By therapy 



  • Anaphylaxis

  • Rheumatoid Arthritis

  • Diabetes

  • Multiple Sclerosis


By type 



  • Reusable auto-injectors 

  • Disposable auto-injectors 


by administration 



  • Intramuscular 

  • Subcutaneous 


By end-user 



  • Ambulatory care 

  • Home care 

  • Hospital care 


By geography 



  • Middle East 

  • Asia pacific 

  • Europe 

  • North America 


Competitive landscape 


The competition in the auto-injector market is rising in the forecast period. The key players will lead to more research and innovation. Market acquisitions, expansion and partnerships are part of the competitive landscape. New product launches and segment expansions are key strategies of the market players. 


Regional analysis 


The auto-injector market is fragmented into Asia Pacific, Europe, Middle East and North America. The Asia Pacific will hold the maximum auto-injector market share. The investment for the health industry is rising in Asia pacific. It will fuel the production of auto-injectors in Asia pacific.


Through partnerships with local pharmacies, the region is expanding its market. North America is the next region with the highest market demand. The adoption of auto-injectors is rapid in this region. Also, the high spending power of customers will lead to more growth of auto-injectors. It is a market with the highest profitability rate in the forecast period. 


The key players of the auto-injector market are 



  1. Merck KGaA

  2. AbbVie Inc

  3. Antares Pharma

  4. Eli Lilly and Company

  5. Teva Pharmaceutical 

  6. Amgen 

  7. Johnson & Johnson

  8. GlaxoSmithKline plc 

  9. Becton, Dickinson and Company


Recent developments 



  1. The key players of the market are signing new projects for the production of auto-injectors in the middle east.  



  1. The key players are introducing auto-injection delivery systems in many regions. 


Report overview 



  1. Market overview highlights 

  2. Analysis based upon COVID 19

  3. Explanation upon the Market Dynamics

  4. Value chain analysis

  5. Market segmentation overview

  6. The regional analysis

  7. Competitive landscape analysis

  8. Recent Developments



Report Scope:
Report Attribute/Metric Details
  Market Size   2025: USD 125.32 million
  CAGR   2019-2025: 22.0%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units    Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   product type, application, distribution channel, end user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Bayer AG, Haselmeier, Novartis AG, Owen Mumford Ltd, Becton, Dickinson and Company, AbbVie Inc., Johnson & Johnson, Amgen Inc., Teva Pharmaceuticals USA, Biogen, Eli Lilly and Company, Mylan NV, Ypsomed AG, Merck KGaA, AstraZeneca, and Kaleo, Inc.
  Key Market Opportunities   availability of alternatives such as continuous glucose monitoring devices
  Key Market Drivers

  • increasing availability of generic auto-injectors
  • growing geriatric population


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    auto-injector market is projected grow at approximately 22% CAGR during the assessment period (2019-2025).

    The valuation of the auto-injector market had reached USD 37.44 MN in 2018.

    The valuation of the auto-injector market is estimated to increase to USD 125.32 MN by the end of 2025.

    North America holds the largest share in the global auto-injector market, followed by Europe and the Asia Pacific, respectively.

    Haselmeier, Bayer AG, Novartis AG, Becton, Dickinson and Company, Owen Mumford Ltd, AbbVie Inc., Amgen Inc., Johnson & Johnson, Teva Pharmaceuticals USA, Eli Lilly and Company, Biogen, Mylan NV, Merck KGaA, Ypsomed AG, Kaleo, Inc., and AstraZeneca, are some of the major players operating in the auto-injector market.

    Table of Contents:

    Chapter 1. Executive Summary

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Overview

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.2.1 R&D and Designing

    5.2.2 Manufacturing

    5.2.3 Distribution & Sales

    5.2.4 Post-Sales Review

    Chapter 6. Global Auto-Injectors Market, by Product Type

    6.1 Overview

    6.2 Disposable

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.3 Reusable

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 8. Global Auto-Injectors Market, by Application

    8.1 Overview

    8.2 Anaphylaxis

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.3 Multiple Sclerosis

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.4 Diabetes

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.5 Allergies

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.6 Rheumatoid Arthritis

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.7 Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 8. Global Auto-Injectors Market, by Distribution Channel

    8.1 Overview

    8.2 Online Retailer

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.3 Pharmacy

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.4 Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 10. Global Auto-Injectors Market, by End User

    10.1 Overview

    10.2 Home Care Settings

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    10.3 Hospitals & Clinics

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    10.4 Ambulatory Surgical Centers

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 11. Global Auto-Injectors Market, by Region

    11.1 Overview

    11.2 Americas

    11.2.1 North America

    11.2.1.1 US

    11.2.1.2 Canada

    11.2.2 Latin America

    11.3 Europe

    11.3.1 Western Europe

    11.3.1.1 Germany

    11.3.1.2 France

    11.3.1.3 Italy

    11.3.1.4 Spain

    11.3.1.5 UK

    11.3.1.6 Rest of Western Europe

    11.3.2 Eastern Europe

    11.4 Asia-Pacific

    11.4.1 Japan

    11.4.2 China

    11.4.3 India

    11.4.4 Australia

    11.4.5 South Korea

    11.4.6 Rest of Asia-Pacific

    11.5 Middle East & Africa

    11.5.1 Middle East

    11.5.2 Africa

    Chapter 12. Company Landscape

    12.1 Overview

    12.2 Competitive Analysis

    Chapter 13. Company Profile

    13.1 Bayer AG

    13.1.1 Company Overview

    13.1.2 Products/Services Offered

    13.1.3 Financial Overview

    13.1.4 Key Developments

    13.1.5 SWOT Analysis

    13.1.6 Key Strategies

    13.2 Haselmeier

    13.2.1 Company Overview

    13.2.2 Products/Services Offered

    13.2.3 Financial Overview

    13.2.4 Key Developments

    13.2.5 SWOT Analysis

    13.2.6 Key Strategies

    13.3 Novartis AG

    13.3.1 Company Overview

    13.3.2 Products/Services Offered

    13.3.3 Financial Overview

    13.3.4 Key Development

    13.3.5 SWOT Analysis

    13.3.6 Key Strategies

    13.4 Owen Mumford Ltd

    13.4.1 Company Overview

    13.4.2 Products/Services Offered

    13.4.3 Financial Overview

    13.4.4 Key Development

    13.4.5 SWOT Analysis

    13.4.6 Key Strategies

    13.5 Becton, Dickinson and Company

    13.5.1 Company Overview

    13.5.2 Products/Services Offered

    13.5.3 Financial overview

    13.5.4 Key Developments

    13.5.5 SWOT Analysis

    13.5.6 Key Strategies

    13.6 AbbVie Inc.

    13.6.1 Company Overview

    13.6.2 Products/Services Offered

    13.6.3 Financial Overview

    13.6.4 Key Developments

    13.6.5 SWOT Analysis

    13.6.6 Key Strategies

    13.7 Johnson & Johnson

    13.7.1 Overview

    13.7.2 Products/Services Offered

    13.7.3 Financial Overview

    13.7.4 Key Developments

    13.7.5 SWOT Analysis

    13.7.6 Key Strategies

    13.8 Amgen Inc.

    13.8.1 Overview

    13.8.2 Products/Services Offered

    13.8.3 Financial Overview

    13.8.4 Key Developments

    13.8.5 SWOT Analysis

    13.8.6 Key Strategies

    13.9 Teva Pharmaceuticals USA

    13.9.1 Overview

    13.9.2 Products/Services Offered

    13.9.3 Financial Overview

    13.9.4 Key Developments

    13.9.5 SWOT Analysis

    13.9.6 Key Strategies

    13.10 Biogen

    13.10.1 Overview

    13.10.2 Products/Services Offered

    13.10.3 Financial Overview

    13.10.4 Key Developments

    13.10.5 SWOT Analysis

    13.10.6 Key Strategies

    13.11 Eli Lilly and Company

    13.11.1 Overview

    13.11.2 Products/Services Offered

    13.11.3 Financial Overview

    13.11.4 Key Developments

    13.11.5 SWOT Analysis

    13.11.6 Key Strategies

    13.12 Mylan N.V.

    13.12.1 Overview

    13.12.2 Products/Services Offered

    13.12.3 Financial Overview

    13.12.4 Key Developments

    13.12.5 SWOT Analysis

    13.12.6 Key Strategies

    13.13 Ypsomed AG

    13.13.1 Overview

    13.13.2 Products/Services Offered

    13.13.3 Financial Overview

    13.13.4 Key Developments

    13.13.5 SWOT Analysis

    13.13.6 Key Strategies

    13.14 Merck KGaA

    13.14.1 Overview

    13.14.2 Products/Services Offered

    13.14.3 Financial Overview

    13.14.4 Key Developments

    13.14.5 SWOT Analysis

    13.14.6 Key Strategies

    13.15 AstraZeneca

    13.15.1 Overview

    13.15.2 Products/Services Offered

    13.15.3 Financial Overview

    13.15.4 Key Developments

    13.15.5 SWOT Analysis

    13.15.6 Key Strategies

    13.16 kaleo, Inc.

    13.16.1 Overview

    13.16.2 Products/Services Offered

    13.16.3 Financial Overview

    13.16.4 Key Developments

    13.16.5 SWOT Analysis

    13.16.6 Key Strategies

    13.13 Others

    Chapter 14 Appendix

    14.1 References

    14.2 Related Reports


    LIST OF TABLES

    Table 1 Global Auto-Injectors Market Synopsis, 2020-2027

    Table 2 Global Auto-Injectors Market Estimates and Forecast, 2020-2027 (USD Million)

    Table 3 Global Auto-Injectors Market, by Product Type, 2020-2027 (USD Million)

    Table 4 Global Auto-Injectors Market, by Application, 2020-2027 (USD Million)

    Table 5 Global Auto-Injectors Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 6 Global Auto-Injectors Market, by End User, 2020-2027 (USD Million)

    Table 7 Global Auto-Injectors Market, by Region, 2020-2027 (USD Million)

    Table 8 Americas: Auto-Injectors Market, by Region, 2020 and 2025

    Table 9 Americas: Auto-Injectors Market, by Product Type, 2020-2027 (USD Million)

    Table 10 Americas: Auto-Injectors Market, by Application, 2020-2027 (USD Million)

    Table 11 Americas: Auto-Injectors Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 12 Americas: Auto-Injectors Market, by End User, 2020-2027 (USD Million)

    Table 13 North America: Auto-Injectors Market, by Country, 2020-2027 (USD Million)

    Table 14 North America: Auto-Injectors Market, by Product Type, 2020-2027 (USD Million)

    Table 15 North America: Auto-Injectors Market, by Application, 2020-2027 (USD Million)

    Table 16 North America: Auto-Injectors Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 17 North America: Auto-Injectors Market, by End User, 2020-2027 (USD Million)

    Table 18 US: Auto-Injectors Market, by Product Type, 2020-2027 (USD Million)

    Table 19 US: Auto-Injectors Market, by Application, 2020-2027 (USD Million)

    Table 20 US: Auto-Injectors Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 21 US: Auto-Injectors Market, by End User, 2020-2027 (USD Million)

    Table 22 Canada: Auto-Injectors Market, by Product Type, 2020-2027 (USD Million)

    Table 23 Canada: Auto-Injectors Market, by Application, 2020-2027 (USD Million)

    Table 24 Canada: Auto-Injectors Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 25 Canada: Auto-Injectors Market, by End User, 2020-2027 (USD Million)

    Table 26 Latin America: Auto-Injectors Market, by Product Type, 2020-2027 (USD Million)

    Table 27 Latin America: Auto-Injectors Market, by Application, 2020-2027 (USD Million)

    Table 28 Latin America: Auto-Injectors Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 29 Latin America: Auto-Injectors Market, by End User, 2020-2027 (USD Million)

    Table 30 Europe: Auto-Injectors Market, by Region, 2020-2027 (USD Million)

    Table 31 Europe: Auto-Injectors Market, by Product Type, 2020-2027 (USD Million)

    Table 32 Europe: Auto-Injectors Market, by Application, 2020-2027 (USD Million)

    Table 33 Europe: Auto-Injectors Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 34 Europe: Auto-Injectors Market, by End User, 2020-2027 (USD Million)

    Table 35 Western Europe: Auto-Injectors Market, by Country, 2020-2027 (USD Million)

    Table 36 Western Europe: Auto-Injectors Market, by Product Type, 2020-2027 (USD Million)

    Table 37 Western Europe: Auto-Injectors Market, by Application, 2020-2027 (USD Million)

    Table 38 Western Europe: Auto-Injectors Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 39 Western Europe: Auto-Injectors Market, by End User, 2020-2027 (USD Million)

    Table 40 Eastern Europe: Auto-Injectors Market, by Product Type, 2020-2027 (USD Million)

    Table 41 Eastern Europe: Auto-Injectors Market, by Application, 2020-2027 (USD Million)

    Table 42 Eastern Europe: Auto-Injectors Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 43 Eastern Europe: Auto-Injectors Market, by End User, 2020-2027 (USD Million)

    Table 44 Asia-Pacific: Auto-Injectors Market, by Country, 2020-2027 (USD Million)

    Table 45 Asia-Pacific: Auto-Injectors Market, by Product Type, 2020-2027 (USD Million)

    Table 46 Asia-Pacific: Auto-Injectors Market, by Application, 2020-2027 (USD Million)

    Table 47 Asia-Pacific: Auto-Injectors Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 48 Asia-Pacific: Auto-Injectors Market, by End User, 2020-2027 (USD Million)

    Table 49 Middle East & Africa: Auto-Injectors Market, by Region, 2020-2027 (USD Million)

    Table 50 Middle East & Africa: Auto-Injectors Market, by Product Type, 2020-2027 (USD Million)

    Table 51 Middle East & Africa: Auto-Injectors Market, by Application, 2020-2027 (USD Million)

    Table 52 Middle East & Africa: Auto-Injectors Market, by Distribution Channel, 2020-2027 (USD Million)

    Table 53 Middle East & Africa: Auto-Injectors Market, by End User, 2020-2027 (USD Million)


    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Market Structure for Global Auto-Injectors Market

    Figure 3 Market Dynamics for Global Auto-Injectors Market

    Figure 4 Global Auto-Injectors Market Share, by Product Type, 2020 (%)

    Figure 5 Global Auto-Injectors Market Share, by Product Type, 2020 (USD Million)

    Figure 6 Global Auto-Injectors Market Share, by Application, 2020 (%)

    Figure 7 Global Auto-Injectors Market Share, by Application, 2020 (USD Million)

    Figure 8 Global Auto-Injectors Market Share, by Distribution Channel, 2020 (%)

    Figure 9 Global Auto-Injectors Market Share, by Distribution Channel, 2020 (USD Million)

    Figure 10 Global Auto-Injectors Market Share, by End User, 2020 (%)

    Figure 11 Global Auto-Injectors Market Share, by End User, 2020 (USD Million)

    Figure 12 Global Auto-Injectors Market Share, by Region, 2020 (%)

    Figure 13 Americas: Auto-Injectors Market Share, by Region, 2020 (%)

    Figure 14 North America: Auto-Injectors Market Share, by Country, 2020 (%)

    Figure 15 Europe: Auto-Injectors Market Share, by Region, 2020 (%)

    Figure 16 Western Europe: Auto-Injectors Market Share, by Country, 2020 (%)

    Figure 17 Asia-Pacific: Auto-Injectors Market Share, by Country, 2020 (%)

    Figure 18 Middle East & Africa: Auto-Injectors Market Share, by Region, 2020 (%)

    Figure 19 Global Auto-Injectors Market: Company Share Analysis, 2020 (%)

    Figure 20 Bayer AG: Key Financials

    Figure 21 Bayer AG: Segmental Revenue

    Figure 22 Bayer AG: Geographical Revenue

    Figure 23 Haselmeier: Key Financials

    Figure 24 Haselmeier: Segmental Revenue

    Figure 25 Haselmeier: Geographical Revenue

    Figure 26 Novartis AG: Key Financials

    Figure 27 Novartis AG: Segmental Revenue

    Figure 28 Novartis AG: Geographical Revenue

    Figure 29 Owen Mumford Ltd: Key Financials

    Figure 30 Owen Mumford Ltd: Segmental Revenue

    Figure 31 Owen Mumford Ltd: Geographical Revenue

    Figure 32 Becton, Dickinson and Company: Key Financials

    Figure 33 Becton, Dickinson and Company: Segmental Revenue

    Figure 34 Becton, Dickinson and Company: Geographical Revenue

    Figure 35 AbbVie Inc.: Key Financials

    Figure 36 AbbVie Inc.: Segmental Revenue

    Figure 37 AbbVie Inc.: Geographical Revenue

    Figure 38 Johnson & Johnson: Key Financials

    Figure 39 Johnson & Johnson: Segmental Revenue

    Figure 40 Johnson & Johnson: Geographical Revenue

    Figure 41 Amgen Inc.: Key Financials

    Figure 42 Amgen Inc.: Segmental Revenue

    Figure 43 Amgen Inc.: Geographical Revenue

    Figure 44 Teva Pharmaceuticals USA: Key Financials

    Figure 45 Teva Pharmaceuticals USA: Segmental Revenue

    Figure 46 Teva Pharmaceuticals USA: Geographical Revenue

    Figure 47 Biogen: Key Financials

    Figure 48 Biogen: Segmental Revenue

    Figure 49 Biogen: Geographical Revenue

    Figure 50 Eli Lilly and Company: Key Financials

    Figure 51 Eli Lilly and Company: Segmental Revenue

    Figure 52 Eli Lilly and Company: Geographical Revenue

    Figure 53 Mylan NV: Key Financials

    Figure 54 Mylan NV: Segmental Revenue

    Figure 55 Mylan NV: Geographical Revenue

    Figure 56 Ypsomed AG: Key Financials

    Figure 57 Ypsomed AG: Segmental Revenue

    Figure 58 Ypsomed AG: Geographical Revenue

    Figure 59 Merck KGaA: Key Financials

    Figure 60 Merck KGaA: Segmental Revenue

    Figure 61 Merck KGaA: Geographical Revenue

    Figure 62 AstraZeneca: Key Financials

    Figure 63 AstraZeneca: Segmental Revenue

    Figure 64 AstraZeneca: Geographical Revenue

    Figure 65 kaleo, Inc.: Key Financials

    Figure 66 kaleo, Inc.: Segmental Revenue

    Figure 67 kaleo, Inc.: Geographical Revenue